scholarly journals Allosteric Activation of Cytochrome P450 3A4 by α-Naphthoflavone: Branch Point Regulation Revealed by Isotope Dilution Analysis

Biochemistry ◽  
2011 ◽  
Vol 50 (46) ◽  
pp. 10041-10051 ◽  
Author(s):  
Caleb M. Woods ◽  
Cristina Fernandez ◽  
Kent L. Kunze ◽  
William M. Atkins
Xenobiotica ◽  
2017 ◽  
Vol 48 (12) ◽  
pp. 1227-1236 ◽  
Author(s):  
Tomohiko Ichikawa ◽  
Hirofumi Tsujino ◽  
Takahiro Miki ◽  
Masaya Kobayashi ◽  
Chiaki Matsubara ◽  
...  

2017 ◽  
Vol 51 (2) ◽  
pp. 157-165
Author(s):  
Le Zhang ◽  
Zhong-Yuan Ren ◽  
Jin-Long Ma ◽  
Xiao-Ping Xia

1984 ◽  
Vol 49 (4) ◽  
pp. 805-820
Author(s):  
Ján Klas

The accuracy of the least squares method in the isotope dilution analysis is studied using two models, viz a model of a two-parameter straight line and a model of a one-parameter straight line.The equations for the direct and the inverse isotope dilution methods are transformed into linear coordinates, and the intercept and slope of the two-parameter straight line and the slope of the one-parameter straight line are evaluated and treated.


2007 ◽  
Vol 79 (7) ◽  
pp. 2859-2868 ◽  
Author(s):  
Dirk Schaumlöffel ◽  
Pierre Giusti ◽  
Hugues Preud'Homme ◽  
Joanna Szpunar ◽  
Ryszard Łobiński

1995 ◽  
Vol 270 (10) ◽  
pp. 5014-5018 ◽  
Author(s):  
Aditya P. Koley ◽  
Jeroen T. M. Buters ◽  
Richard C. Robinson ◽  
Allen Markowitz ◽  
Fred K. Friedman

2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.


Sign in / Sign up

Export Citation Format

Share Document